Interpace Biosciences Announces Third Quarter 2022 Financial and Business Results Sale of Pharma Significantly Improves Liquidity Resulting in Removal of Going Concern Nov 14, 2022
Interpace Biosciences Announces New Real-world Data; Presented at the American Thyroid Association 2022 Annual Meeting Oct 20, 2022
Interpace Biosciences Announces New Clinical Validation Data; Diagnostic Accuracy Significantly Improved Sep 1, 2022
Interpace Biosciences Completes Sale of Its Pharma Services Business to Flagship Biosciences, Inc. Aug 31, 2022
Interpace Biosciences Announces Second Quarter 2022 Financial and Business Results and New Clinical Validation Data; Diagnostic Accuracy Significantly Improved Aug 15, 2022
Miroculus to Optimize Automated Next Generation Sequencing Library Preparation with Interpace Diagnostics and Twist Bioscience May 11, 2022
Interpace Biosciences Announces Full Year and Fourth Quarter 2021 Financial and Business Results Mar 31, 2022
Interpace Biosciences Announces Update of Previously Announced CMS Billing Policy Impacting its Thyroid Tests Feb 22, 2022
Interpace Biosciences Terminates Rights Offering Announces Change in CMS Medicare Reimbursement of its Thyroid Tests Jan 28, 2022
